Related Experiment Video
Updated: May 23, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Effects of a human compact anti-ErbB2 antibody on prostate cancer
Angela Eliana Malara1, Carmine Fedele, Luigi Aloj
1Department of Structural and Functional Biology, University of Naples Federico II, I-80126 Naples, Italy.
Abstract:
Prostate cancer is the most commonly diagnosed malignancy in men in developed countries. ErbB2, a tyrosine kinase receptor overexpressed in many human cancer types, contributes to prostate cancer progression by activating the androgen receptor in a steroid poor environment, thus promoting androgen-independent cell growth. The consequent development of hormone refractory tumors is a major obstacle in prostate cancer therapy. The inhibition of ErbB2 signal transduction pathways by the use of human antibodies could be a valuable alternative strategy for cancer therapy. We performed a comparative analysis in vitro and in vivo of the antitumor effects of three different antibodies targeting different epitopes of ErbB2: Herceptin (trastuzumab), 2C4 (pertuzumab) and Erb-hcAb (human anti-ErbB2-compact antibody), a novel fully human compact antibody produced in our laboratory. Herein, we demonstrate that the growth of both androgen-dependent and independent prostate cancer cells was efficiently inhibited by Erb-hcAb. The antitumor effects induced by Erb-hcAb on some cell lines were more potent than those observed for either Herceptin or 2C4. Thus, Erb-hcAb could be a promising candidate in the immunotherapy of prostate cancer for which no obvious treatment has been reported so far.
Insights
A novel human antibody, Erb-hcAb, shows potent antitumor effects against prostate cancer. This ErbB2-targeting antibody effectively inhibits both androgen-dependent and independent prostate cancer cell growth, offering a promising new immunotherapy strategy.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Prostate cancer is a leading malignancy in developed countries.
- ErbB2 overexpression drives prostate cancer progression and hormone-refractory tumor development.
- Targeting ErbB2 signaling pathways with antibodies is a potential therapeutic strategy.
Purpose of the Study:
- To comparatively analyze the in vitro and in vivo antitumor effects of three ErbB2-targeting antibodies.
- To evaluate a novel fully human compact antibody, Erb-hcAb, against prostate cancer.
- To assess Erb-hcAb's efficacy compared to Herceptin and 2C4.
Main Methods:
- In vitro and in vivo comparative analysis of antibody efficacy.
- Utilized three distinct ErbB2-targeting antibodies: Herceptin, 2C4, and Erb-hcAb.
- Assessed inhibition of androgen-dependent and independent prostate cancer cell growth.
Main Results:
- Erb-hcAb demonstrated efficient inhibition of both androgen-dependent and independent prostate cancer cell growth.
- Erb-hcAb exhibited more potent antitumor effects than Herceptin or 2C4 in certain cell lines.
- The novel compact antibody Erb-hcAb shows significant potential.
Conclusions:
- Erb-hcAb is a promising candidate for prostate cancer immunotherapy.
- This novel antibody overcomes limitations of existing treatments for hormone-refractory prostate cancer.
- Further investigation into Erb-hcAb as a therapeutic agent is warranted.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...